New drug QLS5316 enters first human tests for advanced cancers
NCT ID NCT07358884
First seen Jan 23, 2026 · Last updated May 17, 2026 · Updated 23 times
Summary
This early-stage study tests a new drug called QLS5316 in about 300 people with advanced solid tumors (including colorectal, stomach, head and neck, and lung cancers) who have no other standard treatment options. The main goals are to check the drug's safety, find the right dose, and see if it helps shrink tumors. Participants will receive the drug alone, and the study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.